Key Points
- Michel Lagarde (COO) sold 22,046 shares of Thermo Fisher on Dec. 4 at an average price of $563.56 for $12.42M, and after recent sales on Dec. 2, Dec. 3 and Nov. 13 his stake has fallen by 20.77% to 84,117 shares (≈$47.4M).
- Thermo Fisher reported an earnings beat (Q: $5.79 EPS vs. $5.50 expected; revenue $11.12B), set FY2025 EPS guidance of 22.600–22.860, authorized a $5.0 billion share buyback (≈2.4% of shares), and declared a quarterly dividend of $0.43 ($1.72 annualized, ~0.3% yield).
Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) COO Michel Lagarde sold 22,046 shares of the business's stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $563.56, for a total value of $12,424,243.76. Following the completion of the transaction, the chief operating officer owned 84,117 shares in the company, valued at $47,404,976.52. This trade represents a 20.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Michel Lagarde also recently made the following trade(s):
- On Tuesday, December 2nd, Michel Lagarde sold 30,000 shares of Thermo Fisher Scientific stock. The stock was sold at an average price of $581.92, for a total transaction of $17,457,600.00.
- On Wednesday, December 3rd, Michel Lagarde sold 32,000 shares of Thermo Fisher Scientific stock. The shares were sold at an average price of $583.39, for a total transaction of $18,668,480.00.
- On Thursday, November 13th, Michel Lagarde sold 4,638 shares of Thermo Fisher Scientific stock. The stock was sold at an average price of $594.42, for a total transaction of $2,756,919.96.
Thermo Fisher Scientific Price Performance
NYSE TMO opened at $572.49 on Friday. The firm has a market cap of $215.09 billion, a P/E ratio of 33.07, a price-to-earnings-growth ratio of 4.20 and a beta of 0.90. The stock's 50-day moving average is $559.70 and its two-hundred day moving average is $485.00. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts' consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm's revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific announced that its Board of Directors has authorized a stock repurchase plan on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's leadership believes its shares are undervalued.
Thermo Fisher Scientific Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific's dividend payout ratio is 9.94%.
Analyst Ratings Changes
Several research analysts have commented on TMO shares. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a "neutral" rating in a research report on Thursday, October 23rd. Barclays increased their price target on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an "overweight" rating in a report on Thursday, October 23rd. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Finally, Morgan Stanley lifted their target price on Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an "overweight" rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $602.35.
Check Out Our Latest Research Report on TMO
Institutional Trading of Thermo Fisher Scientific
Institutional investors have recently made changes to their positions in the business. CBIZ Investment Advisory Services LLC boosted its stake in shares of Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares during the last quarter. JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the third quarter worth $28,000. Highline Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock valued at $29,000 after acquiring an additional 33 shares during the period. Anderson Financial Strategies LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter worth approximately $30,000. Finally, Capital A Wealth Management LLC increased its holdings in Thermo Fisher Scientific by 825.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock worth $30,000 after purchasing an additional 66 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.
About Thermo Fisher Scientific
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
